Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Patent ductus arteriosus (PDA) and response to late surfactant treatment in premature infants

Journal of Perinatology volume 43, pages 1245–1251 (2023)Cite this article

Subjects

Objective

To determine the clinical/echocardiography (ECHO) phenotype of patients with hypoxic respiratory failure (HRF) and response to late surfactant, according to patent ductus arteriosus (PDA) status.

Study design

This retrospective study included infants ≤26+6 weeks gestation who received ≥1 surfactant dose after 6 postnatal days and where PDA status was available by ECHO. Response to surfactant was appraised based on change in respiratory severity score over 48 h. The relationship between PDA status and response to surfactant was evaluated via univariate analysis.

Result

We studied late surfactant (n = 71 doses) administration in 35 preterm infants born at a mean weight and GA at birth were 595 g (508, 696) and 23.3 (22.7, 25) weeks, respectively of whom 16 (46%) had a diagnosis of PDA. Positive response to late surfactant treatment was independently associated with absence of PDA [OR 26 (2, 334), p = 0.01] whereas presence of PDA was independently associated with negative response [OR 12 (1.1, 126), p = 0.04].

Conclusions

In neonates ≤26+6 weeks gestation, with HRF, response to surfactant after postnatal day 6 is influenced by PDA status. Future trials should consider PDA status which may enhance diagnostic precision and refine patient selection for late surfactant treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Population description.
Fig. 2: Change in respiratory severity score following surfactant administration.
Fig. 3: Receiver operating characteristic (ROC) curve for PDA score as a predictor of positive and negative response to late surfactant.

Similar content being viewed by others

References

  1. Bell EF, Hintz SR, Hansen NI, Bann CM, Wyckoff MH, DeMauro SB, et al. Mortality, In-Hospital Morbidity, Care Practices, and 2-Year Outcomes for Extremely Preterm Infants in the US, 2013-2018. JAMA. 2022;327:248–63.

    Article  PubMed  Google Scholar 

  2. Jobe AH. Pulmonary surfactant therapy. N. Engl J Med. 1993;328:861–8.

    Article  CAS  PubMed  Google Scholar 

  3. Soll R, Ozek E. Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane database Syst Rev. 2010;2010:Cd001079.

    PubMed  PubMed Central  Google Scholar 

  4. Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2000;2:Cd001079.

    Google Scholar 

  5. Vitali F, Galletti S, Aceti A, Aquilano G, Fabi M, Balducci A, et al. Pilot observational study on haemodynamic changes after surfactant administration in preterm newborns with respiratory distress syndrome. Ital J Pediatrics. 2014;40:26.

    Article  Google Scholar 

  6. Sobel DB, Carroll A. Postsurfactant slump: early prediction of neonatal chronic lung disease? J Perinatol. 1994;14:268–74.

    CAS  PubMed  Google Scholar 

  7. Katz L, Klein J. Repeat surfactant therapy for postsurfactant slump. J Perinatol. 2006;26:414–22.

    Article  CAS  PubMed  Google Scholar 

  8. Ballard RA, Keller RL, Black DM, Ballard PL, Merrill JD, Eichenwald EC, et al. Randomized trial of late surfactant treatment in ventilated preterm infants receiving inhaled nitric oxide. J Pediatrics. 2016;168:23–29.e24.

    Article  CAS  Google Scholar 

  9. Hascoët J-M, Picaud J-C, Ligi I, Blanc T, Moreau F, Pinturier M-F, et al. Late surfactant administration in very preterm neonates with prolonged respiratory distress and pulmonary outcome at 1 year of age: a randomized clinical trial. JAMA Pediatrics. 2016;170:365–72.

    Article  PubMed  Google Scholar 

  10. McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child-Fetal Neonatal Ed. 2007;92:F424–F427.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Sehgal A, Mak W, Dunn M, Kelly E, Whyte H, McCrindle B, et al. Haemodynamic changes after delivery room surfactant administration to very low birth weight infants. Arch Dis Child-Fetal Neonatal Ed. 2010;95:F345–F351.

    Article  PubMed  Google Scholar 

  12. Sehgal A, Bhatia R, Roberts CT. Cardiorespiratory Physiology following Minimally Invasive Surfactant Therapy in Preterm Infants. Neonatology. 2019;116:278–85.

    Article  CAS  PubMed  Google Scholar 

  13. Jung YH, Jang J, Kim HS, Shin SH, Choi CW, Kim EK, et al. Respiratory severity score as a predictive factor for severe bronchopulmonary dysplasia or death in extremely preterm infants. BMC Pediatr. 2019;19:121.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Mertens L, Seri I, Marek J, Arlettaz R, Barker P, McNamara P, et al. Targeted Neonatal Echocardiography in the Neonatal Intensive Care Unit: practice guidelines and recommendations for training. Writing Group of the American Society of Echocardiography (ASE) in collaboration with the European Association of Echocardiography (EAE) and the Association for European Pediatric Cardiologists (AEPC). J Am Soc Echocardiogr. 2011;24:1057–78.

    Article  PubMed  Google Scholar 

  15. Bischoff AR, Giesinger RE, Rios DR, Mertens L, Ashwath R, McNamara PJ. Anatomic Concordance of Neonatologist-Performed Echocardiography as Part of Hemodynamics Consultation and Pediatric Cardiology. J Am Soc Echocardiogr. 2021;34:301–7.

    Article  PubMed  Google Scholar 

  16. Rios DR, Martins FF, El-Khuffash A, Weisz DE, Giesinger RE, McNamara PJ. Early Role of the Atrial-Level Communication in Premature Infants with Patent Ductus Arteriosus. J Am Soc Echocardiogr. 2021;34:423–32.e421.

    Article  PubMed  Google Scholar 

  17. Sindelar R, Nakanishi H, Stanford AH, Colaizy TT, Klein JM. Respiratory management for extremely premature infants born at 22 to 23 weeks of gestation in proactive centers in Sweden, Japan, and USA. Semin Perinatol. 2021;46:151540 https://doi.org/10.1016/j.semperi.2021.151540.

  18. Merrill JD, Ballard RA, Cnaan A, Hibbs AM, Godinez RI, Godinez MH, et al. Dysfunction of pulmonary surfactant in chronically ventilated premature infants. Pediatr Res. 2004;56:918–26.

    Article  CAS  PubMed  Google Scholar 

  19. Deshpande P, Baczynski M, McNamara PJ, Jain A. Patent ductus arteriosus: The physiology of transition. Semin Fetal Neonatal Med. 2018;23:225–231.

  20. Haworth SG. Pulmonary endothelium in the perinatal period. Pharmacol Rep. 2006;58:153.

    PubMed  Google Scholar 

  21. Davis P, Turner-Gomes S, Cunningham K, Way C, Roberts R, Schmidt B. Precision and accuracy of clinical and radiological signs in premature infants at risk of patent ductus arteriosus. Arch Pediatrics Adolesc Med. 1995;149:1136–41.

    Article  CAS  Google Scholar 

  22. Kindler A, Seipolt B, Heilmann A, Range U, Rüdiger M, Hofmann SR. Development of a diagnostic clinical score for hemodynamically significant patent ductus arteriosus. Front Pediatrics. 2017;5:280.

    Article  Google Scholar 

  23. de Boode W, Kluckow M, McNamara P, Gupta S. Role of neonatologist-performed echocardiography in the assessment and management of patent ductus arteriosus physiology in the newborn. Semin Fetal Neonatal Med. 2018;23:292–297.

  24. Skelton R, Evans N, Smythe J. A blinded comparison of clinical and echocardiographic evaluation of the preterm infant for patent ductus arteriosus. J Paediatrics Child Health. 1994;30:406–11.

    Article  CAS  Google Scholar 

  25. Dice JE, Bhatia J. Patent ductus arteriosus: an overview. J Pediatr Pharmacol Therapeutics. 2007;12:138–46.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stead Family Department of Pediatrics, The University of Iowa, Iowa City, IA, USA

    Madeline S. Beauchene, Alison M. Cunningham, Amy H. Stanford, Adrianne R. Bischoff, John M. Dagle, Danielle R. Rios, Jonathan M. Klein, Regan E. Giesinger & Patrick J. McNamara

  2. Department of Internal Medicine, The University of Iowa, Iowa City, IA, USA

    Patrick J. McNamara

Authors
  1. Madeline S. Beauchene
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alison M. Cunningham
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amy H. Stanford
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Adrianne R. Bischoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John M. Dagle
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Danielle R. Rios
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jonathan M. Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Regan E. Giesinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Patrick J. McNamara
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: MS.B, REG and PJM; Data curation: MSB, AMC, AHS, ARB, JMD, DRR, JMK, REG; Formal analysis: MSB, AHS, REG; Methodology: MSB, JMD, DRR, REG and PJM; Supervision: AHS, ARB, JMD, DRR, JMK, REG and PJM; Writing—original draft: MSB, AHS; Writing—review & editing: MSB, AMC, AHS, ARB, JMD, DRR, JMK, REG and PJM. All authors have read and agreed to the published version of the manuscript.

Corresponding author

Correspondence to Patrick J. McNamara.

Ethics declarations

Competing interests

The authors declare no competing interests.

Informed Consent Statement

Patient consent was waived due to the retrospective nature of the study.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the University of Iowa (protocol code 20140743).

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beauchene, M.S., Cunningham, A.M., Stanford, A.H. et al. Patent ductus arteriosus (PDA) and response to late surfactant treatment in premature infants. J Perinatol 43, 1245–1251 (2023). https://doi.org/10.1038/s41372-023-01689-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41372-023-01689-2

This article is cited by

Search

Advanced search

Quick links